On December, 14th at 11:00 am , we will hold a webinar on the “Phase I and Bioequivalence clinical trials” . Early phase studies is the most important stage of the drug development process. Firstly, volunteers and patients take medicine for the...
On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221. Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics...